Why the study?
The study was conducted to evaluate the prognostic impact of the evolution of evidence-based treatments in a real-world primary percutaneous coronary intervention registry.
Does the evolution of evidence-based treatments (including newer P2Y12 inhibitors and complete revascularization) improve 5-year clinical outcomes in STEMI patients undergoing primary PCI?
Does the evolution of evidence-based treatments (including newer P2Y12 inhibitors and complete revascularization) improve 5-year clinical outcomes in STEMI patients undergoing primary PCI?
The evolution of STEMI treatments over the last decade, particularly the use of newer P2Y12 inhibitors and complete revascularization, is associated with significantly improved 5-year survival and reduced ischemic events in real-world practice.
Answers are grounded in this paper and cite their sources.
Newer treatments were associated with lower 5-year mortality in STEMI; leaves open whether evolution drove outcomes or reflects unmeasured changes.
OBJECTIVE: To evaluate in a real-world primary percutaneous coronary intervention (pPCI) registry the impact of the evolution of evidence-based treatments on prognosis. METHODS: STEMI patients undergoing pPCI at the University Hospital of Trieste, Italy, were enrolled. The first cohort (old treatments cohort) included STEMI patients treated between January-2007 and December-2012, and the second cohort (new treatments cohort), between January-2013 and December-2020. Inverse Probability of Treatment Weighting (IPTW) Cox regression models as well as multivariable Cox regression models were performed to assess the risk of a composite primary endpoint (PE) of all cause death, reinfarction and re-PCI at 5 years. RESULTS: A total of 2425 STEMI patients were enrolled. At multivariable Cox regression, the new-treatments cohort had lower risk of PE and mortality. Weighted (IPTW) Cox proportional hazard models confirmed the lower risk of the new treatments cohort for PE (HR 0.72; 95% CI 0.56-0.91, p = 0.007) and 5-year mortality (HR 0.70, 95%CI 0.54-0.91, p = 0.009). When considering both clinical and procedural variables, complete revascularization (HR 0.46, 95%CI 0.27-0.80, p = 0.006) and the administration of prasugrel or ticagrelor (HR 0.72, 95%CI 0.52-0.99, p = 0.013) were independent predictors of PE as well as of 5-year mortality. Patients receiving prasugrel or ticagrelor or drug eluting stent were at lower risk of 1-year stent thrombosis (HR 0.50, 95%CI 0.28-0.90, p = 0.021). CONCLUSIONS: In a real-word STEMI population the prognosis of patients has improved in the last decades, and this was associated to the use of new antithrombotic treatments and to the implementation of complete revascularization.
No takes yet. Share an insight, caveat, or question.
Fabris et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: